PRINCETON, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. announces the release of a new randomized controlled clinical trial abstract. As a follow-up to last week’s announcement of the clinical results from the 108-patient randomized and controlled leg ulcer study, in which MEDIHONEY became the first advanced wound care dressing proven to accelerate healing in stalled leg ulcers under compression therapy, the results can now be viewed online.
The Active Leptospermum Honey product used in the study, Comvita’s WoundCare18+, has since been rebranded to MEDIHONEY.
To view the abstract of the study, please click:
http://www.ncbi.nlm.nih.gov/pubmed/18752540?ordinalpos=2&itool=EntrezSystem2.P
Entrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
(Please copy and paste into your web browser.)
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound- care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey- based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company’s novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The University of Southern California in Q4 of 2007 and is entering into a Phase II study, with anticipated initial patient enrollment to begin in Q3 of 2008. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.
CONTACT: Edward J. Quilty, Chairman and CEO of Derma Sciences, Inc.,
+1-609-514-4744, equilty@dermasciences.com; or US Investors, Rudy Barrio
r.barrio@allencaron.com, or media, Brian Kennedy, +1-212-691-8087,
brian@allencaron.com, both of Allen & Caron Inc, for Derma Sciences, Inc.
Web site: http://www.dermasciences.com//
